Title | Ibritumomab tiuxetan plus BEAM in refractory Diffuse Large B-cell Lymphoma
First author | Vít Procházka

According to the International Committee of Medical Journal Editors (ICMJE) ([http://www.icmje.org/ethical_1author.html](http://www.icmje.org/ethical_1author.html)):

“Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The responsible author(s) of this manuscript confirm(s) that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Specific contributions of each author are listed on page 2 of this document.

Responsible author(s):

author(s) responsible for the integrity of the work as a whole

Name: Vít Procházka, MD, Ph.D. 
Institute: Dept. of Hemato-oncology, University Hospital in Olomouc, Czech Republic
E-mail: vit.prochazka@fnol.cz

Name: Antonín Hluší, MD, Ph.D. 
Institute: Dept. of Hemato-oncology, University Hospital in Olomouc, Czech Republic
E-mail: antonin.hlusi@fnol.cz
Author contributions (maximum 1 page):

Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, collection of images, interpretation of data, preparation of the text, etc.)

VP – preparation of the manuscript, interpretation of data
AH – preparation of the manuscript